Cephalon Can't Dodge Provigil Claims In FCA Off-Label Suit
A Pennsylvania federal judge Thursday denied a bid by Cephalon Inc. to dismiss claims in a False Claims Act suit relating to off-label marketing of its drug Provigil, saying a recent...To view the full article, register now.
Already a subscriber? Click here to view full article